Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma

Urologic Oncology
Anh PhamSumanta Pal

Abstract

The advent of novel targeted agents for metastatic renal cell carcinoma (RCC) has offered clinical benefits over traditional immunotherapy (e.g., interleukin-2 and interferon-α) in both efficacy and safety profiles. The major classes of these targeted therapies for metastatic RCC include the tyrosine-kinase inhibitors, monoclonal antibody against vascular endothelial growth factor, and inhibitors of the mammalian target of rapamycin. Most recently, the success of immune checkpoint inhibitors-notably antibodies directed against programmed death-1 and its ligand-has also been demonstrated in RCC. With such progress in therapy, early detection, and subsequent management of treatment-related adverse events allow for patients to remain on active therapy for as long as possible and also enhance the probability of patients tolerating subsequent second line options. However, despite such impressive gains in efficacy with these new agents, therapeutic progress are primarily palliative in nature-hence, the critical importance of minimizing discomfort and potential harm in this patient population cannot be understated.

References

Mar 4, 2000·Journal of Pain and Symptom Management·S KornblauS Wadler
Apr 29, 2004·Transplantation·Phuong-Thu T PhamAlan H Wilkinson
May 4, 2004·Nature Reviews. Cancer·Mary-Ann Bjornsti, Peter J Houghton
Jul 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hope S RugoGeorge Wilding
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Mar 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura Q M Chow, S Gail Eckhardt
May 12, 2007·European Urology·Paul C M S Verhagen
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Jun 15, 2007·Journal of the National Cancer Institute·Darren R FeldmanRobert J Motzer
Dec 18, 2007·The Medical Letter on Drugs and Therapeutics
Oct 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Feb 10, 2009·Cancer Immunology, Immunotherapy : CII·Jeffrey Weber
Apr 1, 2009·Nature Reviews. Clinical Oncology·Francesco TorinoGiampietro Gasparini
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierRonald M Bukowski
May 29, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G Di LorenzoS De Placido
May 29, 2009·AJNR. American Journal of Neuroradiology·K J CarpenterF R Murtagh
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Jul 21, 2009·The Lancet Oncology·Martin E GoreRonald Bukowski
Dec 2, 2009·Clinical Journal of Oncology Nursing·Patricia A Creel
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cora N SternbergRobert E Hawkins
Mar 20, 2010·Clinical Transplantation·Josep M CampistolEggert Stockfleth
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierVesna Sneller
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniEric J Small
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katarzyna D ChmielRichard Kefford
Apr 13, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Camillo PortaRobert J Motzer
Feb 14, 2012·Investigational New Drugs·Roger B Cohen, Stéphane Oudard
Aug 24, 2013·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Feb 25, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y G NajjarB I Rini
Apr 2, 2014·Transplantation Reviews·Bruce KaplanJason R Wellen
May 3, 2014·Journal of Clinical and Experimental Dentistry·Irene Belenguer-GuallarAriadna Claramunt-Lozano
Jun 17, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Michael S EwerRobert J Motzer

❮ Previous
Next ❯

Citations

Nov 21, 2015·Urologic Oncology·Sumanta K PalDaniel Y C Heng
Jun 29, 2016·Immunotherapy·Matthew ZibelmanElizabeth R Plimack
Aug 5, 2016·British Journal of Cancer·Basma Greef, Tim Eisen
Dec 13, 2016·International Journal of Molecular Sciences·Aleksandra Semeniuk-WojtaśStanisław Niemczyk
Mar 16, 2017·The Journal of Urology·Jessie GillsEugene K Lee
Dec 1, 2019·BMC Urology·Christopher S HollenbeakJay D Raman
Mar 27, 2021·Cancer Chemotherapy and Pharmacology·Łukasz MielczarekAnna M Czarnecka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cellular Immunometabolism

Immunometabolism involves not only the way metabolites are digested by the immune system, but the way in which they can alter the pathway of the immune system. These responses occur in day-to-day healthy cell functioning, but can result in diseases, such as autoimmune disorders. Discover the latest research on cellular immunometabolism here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.